Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-02-27
2007-02-27
Huff, Sheela J. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388100, C530S388220, C530S388850, C530S391300, C530S391700, C424S133100, C424S135100, C424S141100, C424S143100, C424S156100, C424S181100, C424S183100, C435S069600
Reexamination Certificate
active
10435614
ABSTRACT:
This invention provides novel antibodies that specifically bind to the cancer antigen MUC-1. The antibodies are useful targeting moieties for specifically directing imaging agents and various therapeutic moieties to a cancer.
REFERENCES:
patent: 5506343 (1996-04-01), Kufe
patent: 5744144 (1998-04-01), Finn et al.
patent: 5827666 (1998-10-01), Finn et al.
patent: 5846746 (1998-12-01), Gipson
patent: 5851829 (1998-12-01), Marasco et al.
patent: 6114129 (2000-09-01), Agrawal et al.
patent: 6224866 (2001-05-01), Barbera-Guillem
patent: 6245752 (2001-06-01), Barbera-Guillem et al.
patent: 6251616 (2001-06-01), Barbera-Guillem et al.
patent: 6365124 (2002-04-01), Babino et al.
patent: 6387888 (2002-05-01), Mincheff et al.
patent: 6418338 (2002-07-01), Barbera-Guillem et al.
patent: 6514942 (2003-02-01), Ioannides et al.
patent: 6521404 (2003-02-01), Griffiths et al.
patent: 6544731 (2003-04-01), Griffiths et al.
patent: 6548643 (2003-04-01), McKenzie et al.
patent: 6555313 (2003-04-01), Griffiths et al.
patent: WO 96/03502 (1996-02-01), None
patent: WO 99/40881 (1999-08-01), None
Alberts et al. Molecular Biology of the Cell, 3rd ed, pp. 1216-1218, 1994.
Coleman P. M. Research in Immunology, 145:33-36, 1994.
Barratt-Boys (1996) “Making the most of mucin: a novel target for tumor immunotherapy.”Cancer Immunol Immunother43:142-151.
Bieche and Lidereau (1997) “A Gene Dosage Effect Is Responsible for High Overexpression of the MUC1 Gene Observed in Human Breast Tumors.”Cancer Genet Cyogenet98:75-80.
Clackson et al. (1991) “Making antibody fragements using phage display libraries.”Nature352:624-628.
Denardo et al. (1991) “Quantitive Imaging of Mouse L-6 Monoclonal Antibody in Breast Cancer Patients to Develop a Therapeutic Strategy.”Nucl. Med. Biol.18(6):621-631.
Denardo et al. (1997) “Radioimmunotherapy for Breast Cancer Using Indium-111/Yttrium-90 BrE-3: Results of a Phase I Clinical Trial”The Journal of Nuclear Medicine38(8) 1180-1185.
Dong et al. (1997) “Expression of MUC1 and MUC2 Mucins in Epithelial Ovarian Tumors.”Journal of Pathology183:311-317.
Fontenot et al. (1993) “Biophysical Characterization of One-, Two-, and Three-Tandem Repeats of Human Mucin (muc-1) Protein Core.”Cancer Research53:5386-5394.
Henderson et al. (1998) “Retroviral Expression of MUC-1 Human Tumor Antigen with Intact Repeat Structure and Capacity to Elicit Immunity In Vivo.”Journal of Immunotherapy. 21 (4): 247-256.
Hoogenboom et al. (1998) “Antibody phage display technology and its applications.”0Immunothechnology4:1-20.
Kotera et al. (1994) “Munoral Immunity against a Tandem Repeat Epitope of Human Mucin MUC-1 in Sera from Breast, Pancreatic, and Colon Cancer Patients.”Cancer Research54:2856-2860.
Lipcon et al. (1998) “Initial Clinical Evaluation of Radiolabeled MX-DTPA Humanized BrE-3 Antibody in Patients with Advanced Breast Cancer.”Clinical Cancer Research4:1679-1688.
Maraveyas et al. (1994) “Pharmacokinetics and Toxicity of an Yttrium -90-CITC-DTPA-HMFG1 Radioimmunoconjugate for Intraperitoneal Radioimmunotherapy of Ovarian Cancer.”Cancer73:1067-1075.
Maziere et al. (1986) “Early Increase in Phosphatidyl Choline Synthesis by Choline and Transmethylation Pathways in Spreading Fibroblasts.”Ex. Cell Res.167:257-261.
McGuckin et al. (1995) “Prognostic Significance of MUC1 Epithelial Mucin Expreaaion in Breast Cancer.”Human Pathology26:432-439.
Taylor-Papadimitriou et al. (1999) “MUC1 and Cancer.”Biochimica et Biophysical Acta1455:301-313.
Pavlinkova et al. (1999) “Pharmacokinetics and Biodistribution of Engineered Single-Chain Antibody Constructs of Mab CC49 in Colon Carcinoma Xenografts.”The Journal of Nuclear Medicine40(9):1536-1546.
Pemberton et al. (1996) “The Epithelial Mucin MUC1 Contains at Least Two Discrete Signals Specifying Membrane Localization of Cells.”The Journal of Biological Chemistry271(4): 2332-2340.
Peterson et al. (1991) “Molecular Analysis of Epitopic Heterogeneity of the Breast Mucin.”Breast Epithelial Antigenspp. 55-68.
Press et al. (1993) “Radiolameled-antibody Therapy of B-Cell Lymphoma with Autologous Bone Marrow Support.”The New Endland Journal of Medicine329(17): 1219-1224.
Price et al. (1998) “Summary Report on the ISOBM TD-4 Workshop: Analysis of 56 Monoclonal Antibodies against the MUC1 Mucin.”Tumor Biology16:1-20.
Quin and McGuckin (2000) “Phosphorylation of the Cytoplasmic Domain of the MUC1 Mucin Correlates with Changes in Cell—Cell Adhesion.”Int. J. Cancer87:499-506.
Regimbald et al. (1996) “The Breast Mucin MUC1 as a Novel Adhesion Ligand for Endothelial Intracellular Adhesion Molecule 1 in Breast Cancer.”Cancer Research56:4244-4249.
Stewart and Brunjes (1993) “Spatial organization and plasticity of the primary and secondary olfactory projections in goldfish.”Brain Research628:243-253.
Viti et al. (1999) “Increased Binding Affinity and Valence of Recombinant Antibody Fragments Lead to Improved Targeting of Tumoral Angiogenesis.”Cancer Research59:347-352.
Winter et al. (1994) Making Antibodies by Phage Display Technology.Annu. Rev. Immunology12:433-455.
Asano et al. (2000) J. Biochem. vol. 127 pp. 673-679.
Apostolopoulos et al. (1994) Critical Reviews in Immunology vol. 14, No. 3&4, pp. 293-309.
Bandyopadhyay et al. (2002) Intl. Journal of Cancer Supplement No. 13, p. 88.
Denton (1999) Cancer Immunol Immunother. 48: pp. 29-38.
Fiorentini et al. (1997) Immunotechnology vol. 3, pp. 45-49.
Hartman et al. (1999) Intl. Journal of Cancer (82) pp. 256-267.
Hoogenboom et al. (2000) Immunology Today vol. 21, No. 8, pp. 371-378.
Hudson (1999) Current Biology Ltd. vol. 11, No. 5, pp. 548-557.
Paul (1993) Fundamental Immunology, 3rdEd. pp. 292-295.
Price et al. (1998) Tumor Biol. 19: pp. 1-20.
Rudikoff et al. (1982) Proc. Natl. Acad. Sci. USA (79) pp. 1979-1983.
Denardo Gerald Louis
Denardo Sally Joan
Winthrop Michelle Denise
Xiong Cheng-Yi
Beyer & Weaver, LLP
Blanchard David J.
Huff Sheela J.
Hunter Tom
The Regents of the University of California
LandOfFree
Anti-MUC-1 single chain antibodies for tumor targeting does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-MUC-1 single chain antibodies for tumor targeting, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-MUC-1 single chain antibodies for tumor targeting will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3873278